Molecular Mechanism of Rectal Insulin Signalling in Inflammatory Bowel Disease

A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Cellular Pathology".

Deadline for manuscript submissions: closed (20 April 2024) | Viewed by 1552

Special Issue Editor


E-Mail Website
Guest Editor
Department of Cellular and Molecular Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Interests: inflammatory bowel disease; rectal insulin treatment; insulin signaling in the colonocyte; intestinal development and morphogenesis
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Intestinal epithelial cells harbor insulin receptors on their basolateral membranes. The physiological role of signaling through the insulin receptor in the intestinal epithelium remains elusive (if it exists at all). Mouse inactivation experiments have demonstrated that these insulin receptors do not play a role in intestinal development. However, under specific conditions, such as during high-fat diet-induced obesity, a phenotype can be elicited. Intriguingly, this phenotype includes changes in the number of certain enteroendocrine cells. In Ulcerative Colitis, insulin receptor mRNA can be upregulated in mucosal biopsies. Furthermore, immunohistochemistry revealed a correlation between this upregulation and increased amounts of insulin receptor immunoreactivity on the basolateral membranes of colonocytes. Subsequent experiments showed that rectally instilled insulin in mice with chemically induced colitis attenuated the inflammation. Collectively, these findings allow pharmacological targeting of epithelial insulin receptors using a local administration approach to treat inflammatory bowel diseases.

This Special Issue aims to compile original data and reviews that shed light on the molecular mechanisms underlying the anti-inflammatory effects observed with luminal insulin treatment. Papers exploring the effects of luminal insulin treatment on intestinal organoids or other cell types, such as enteroendocrine cells and even the microbiota, are also within the scope of this Special Issue.

Prof. Dr. Jørgen Olsen
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • inflammatory bowel disease
  • insulin receptor
  • enteroendocrine cells
  • rectal insulin treatment
  • inflammation
  • microbiota
  • differentiation
  • local administration

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

15 pages, 728 KiB  
Review
Mechanisms of Insulin Signaling as a Potential Therapeutic Method in Intestinal Diseases
by Sara Jarmakiewicz-Czaja, Aneta Sokal-Dembowska, Katarzyna Ferenc and Rafał Filip
Cells 2024, 13(22), 1879; https://doi.org/10.3390/cells13221879 - 14 Nov 2024
Viewed by 1265
Abstract
Gastrointestinal diseases are becoming a growing public health problem. One of them is inflammatory bowel disease (IBD), which includes ulcerative colitis (UC) and Crohn’s disease (CD). The incidence of IBD is increasing in developing countries and declining in developed countries, affecting people of [...] Read more.
Gastrointestinal diseases are becoming a growing public health problem. One of them is inflammatory bowel disease (IBD), which includes ulcerative colitis (UC) and Crohn’s disease (CD). The incidence of IBD is increasing in developing countries and declining in developed countries, affecting people of all ages. Researchers have been exploring new treatment options including insulin signaling pathways in the inflammation of the gastrointestinal tract. It seems that a better understanding of the mechanism of IGF-1, GLP-1 and TL1A on the gut microbiota and inflammation may provide new advances in future therapeutic strategies for patients with IBD, but also other intestinal diseases. This review aims to synthesize insights into the effects of GLP, IGF and anti-TL1A on inflammation and the gut microbiota, which may enable their future use in therapy for people with intestinal diseases. Full article
Show Figures

Figure 1

Back to TopTop